{"disease":{"id":"anti-infective-agents","name":"anti infective agents"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07189858","title":"Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections - Canada","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4740,"lead_sponsor_name":"Ondine Biomedical Inc.","has_results":false},{"nct_id":"NCT06702878","title":"Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4514,"lead_sponsor_name":"Ondine Biomedical Inc.","has_results":false},{"nct_id":"NCT01690533","title":"Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease","phase":"","overall_status":"COMPLETED","enrollment_count":497,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04448665","title":"Compliance of Initial Empiric Antimicrobial Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":267,"lead_sponsor_name":"Military Institute od Medicine National Research Institute","has_results":false},{"nct_id":"NCT04210713","title":"Neuroimmune Dysfunction in Alcohol Use Disorder","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT04365101","title":"Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":86,"lead_sponsor_name":"Celularity Incorporated","has_results":false},{"nct_id":"NCT03279120","title":"Safety, PK, and PD Study of IVRs Releasing TFV and LNG","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"CONRAD","has_results":false},{"nct_id":"NCT04310592","title":"Natural Killer Cell (CYNK-001) Infusions in Adults with AML","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Celularity Incorporated","has_results":false},{"nct_id":"NCT05979207","title":"Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Medicines for Malaria Venture","has_results":true},{"nct_id":"NCT02242968","title":"Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products","phase":"","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT04489420","title":"Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Celularity Incorporated","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}